×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
OTCMKTS:GTBP

GT Biopharma Stock Forecast, Price & News

$2.88
-0.11 (-3.68%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.76
$3.05
50-Day Range
$1.64
$3.11
52-Week Range
$1.51
$15.44
Volume
204,296 shs
Average Volume
274,410 shs
Market Capitalization
$87.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

GT Biopharma Stock Forecast (MarketRank)

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
629.2% Upside
$21.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.65) to ($0.56) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.40 out of 5 stars

30 days | 90 days | 365 days | Advanced Chart

Receive GTBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GT Biopharma and its competitors with MarketBeat's FREE daily newsletter.

GT Biopharma logo

About GT Biopharma (OTCMKTS:GTBP)

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

GTBP Stock News Headlines

GT Biopharma names Manu Ohri as CFO
GT Biopharma Appoints Manu Ohri as Chief Financial Officer
GT BioPharma to Host a Management Update Conference Call
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:GTBP
Previous Symbol
OTCMKTS:OXISD
Fax
N/A
Employees
8
Year Founded
N/A

Company Calendar

Last Earnings
5/16/2022
Today
7/03/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$21.00
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
+629.2%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
1 Analysts

Profitability

Net Income
$-58.01 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.72 per share

Miscellaneous

Free Float
27,707,000
Market Cap
$87.84 million
Optionable
Not Optionable
Beta
0.49














GT Biopharma Frequently Asked Questions

Should I buy or sell GT Biopharma stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GT Biopharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GT Biopharma stock.
View analyst ratings for GT Biopharma
or view top-rated stocks.

What is GT Biopharma's stock price forecast for 2022?

1 brokerages have issued twelve-month target prices for GT Biopharma's shares. Their GTBP stock forecasts range from $18.00 to $24.00. On average, they expect GT Biopharma's stock price to reach $21.00 in the next year. This suggests a possible upside of 629.2% from the stock's current price.
View analysts' price targets for GT Biopharma
or view top-rated stocks among Wall Street analysts.

How has GT Biopharma's stock price performed in 2022?

GT Biopharma's stock was trading at $3.05 at the start of the year. Since then, GTBP stock has decreased by 5.6% and is now trading at $2.88.
View the best growth stocks for 2022 here
.

When is GT Biopharma's next earnings date?

GT Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for GT Biopharma
.

How were GT Biopharma's earnings last quarter?

GT Biopharma, Inc. (OTCMKTS:GTBP) issued its earnings results on Monday, May, 16th. The company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.31) by $0.14.
View GT Biopharma's earnings history
.

Who are GT Biopharma's key executives?

GT Biopharma's management team includes the following people:
  • Mr. Michael Martin Breen, Interim CEO & Exec. Chairman (Age 59, Pay $378.02k)
  • Dr. Gregory I. Berk M.D., Pres of R&D, Chief Medical Officer and Member of Scientific Advisor Board (Age 64, Pay $526.39k)
  • Dr. Gavin S. Choy MBA, PharmD, Chief Clinical Devel. Officer
  • Mr. Manu Ohri, Chief Financial Officer (Age 67)
  • Dr. Jeffrey S. Miller M.D., Consulting Chief Scientific Officer & Scientific Advisor
  • Ms. Stacy Herb M.B.A., M.P.H., Sr. VP of Portfolio Management

What other stocks do shareholders of GT Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GT Biopharma investors own include Cronos Group (CRON), (CGC), Canopy Growth (WEED), Auxly Cannabis Group (CBWTF), KushCo (KSHB), Aurora Cannabis (ACBFF), Alibaba Group (BABA), Cara Therapeutics (CARA), American Cannabis (AMMJ) and GW Pharmaceuticals (GWPH).

What is GT Biopharma's stock symbol?

GT Biopharma trades on the OTCMKTS under the ticker symbol "GTBP."

How do I buy shares of GT Biopharma?

Shares of GTBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GT Biopharma's stock price today?

One share of GTBP stock can currently be purchased for approximately $2.88.

How much money does GT Biopharma make?

GT Biopharma (OTCMKTS:GTBP) has a market capitalization of $87.84 million. The company earns $-58.01 million in net income (profit) each year or ($1.01) on an earnings per share basis.

How many employees does GT Biopharma have?

GT Biopharma employs 8 workers across the globe.

How can I contact GT Biopharma?

GT Biopharma's mailing address is 9350 Wilshire Blvd. Suite 203, Beverly Hills CA, 90212. The official website for GT Biopharma is www.gtbiopharma.com. The company can be reached via phone at (800) 304-9888 or via email at info@oxis.com.

This page (OTCMKTS:GTBP) was last updated on 7/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.